[Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Studies of the Clinical Pharmacokinetics of Allopurinol/3rd Communication: Allopurinol/oxipurinol bioavailability and pharmacokinetics following the administration of a controlled release allopurinol formulation. Regarding the results of our studies on the localization of the absorption of allopurinol and the kinetic behavior of allopurinol/oxipurinol following multiple administration the bioavailability and kinetic properties of the drug delivered from controlled release tablets were studied in healthy volunteers. Allopurinol controlled release tablets (Sigapurol CR), containing 200 mg of the drug characterized by rapid absorption and 100 mg characterized by pH-dependent delivery, were identified as a formulation with advantages pharmacokinetic properties.
D000328:Adult; D000493:Allopurinol / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010117:Oxypurinol / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism*; D011743:Pyrimidines / Q000378:metabolism*; D013535:Suspensions; D013810:Therapeutic Equivalency
D003692:Delayed-Action Preparations; D011743:Pyrimidines; D013535:Suspensions; D000493:Allopurinol; D010117:Oxypurinol
Untersuchungen zur klinischen Pharmakokinetik von Allopurinol. 3. Mitteilung: Allopurinol/Oxipurinol-Pharmakokinetik nach Verabreichung einer Allopurinol-Formulierung mit verzögerter Freisetzung.